HALOZYME THERAPEUTICS, INC.
Halozyme is a biopharmaceutical company headquartered in San Diego, California, that develops drug-delivery technologies and drug-device combination products for biopharmaceutical partners, as well as proprietary products. Its ENHANZE technology uses the enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids. Halozyme licenses ENHANZE to partners for use with their compounds and receives upfront license fees, event- and sales-based milestone payments, revenue from bulk rHuPH20 sales, and royalties on commercial sales. It also licenses Hypercon technology, a microparticle approach to concentrating drugs, and is developing Surf Bio technology for concentrated subcutaneous delivery. Halozyme develops, manufactures and commercializes auto-injector products and supports partner device programs. Its commercial portfolio includes Hylenex, a formulation of rHuPH20, and XYOSTED, a testosterone injection using its auto-injector technology. It also commercializes auto-injector products with Teva and has development programs with Viatris.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HALO in the last 7 days.
H.C. Wainwright reiterated a Buy rating and $130 price target for Halozyme (HALO) after Takeda's trial data showed its immunoglobulin treatment reduced infusion times. The stock is near its 52-week high, up 82% in a year. Halozyme also completed a $1.5B convertible notes offering and won a patent case against Merck. The FDA approved a cancer treatment using Halozyme's technology.
Todd Gordon of Inside Edge Capital suggests rotating out of tech and highlights Halozyme Therapeutics, citing its better-than-expected performance and raised full-year guidance.
Analysts updated ratings and price targets for several companies. Notable changes include Crocs upgraded to Overweight with a target of $139, IBM's target raised to $238, Microsoft's target increased to $675, and Morgan Stanley's target cut to $185. Other companies received mixed recommendations and target adjustments.
Recent HALO coverage spans regulation, financial news and technology.
In the last 30 days, HALO insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($6.6M). The most active reporter was Torley Helen, PRESIDENT AND CEO, with 12 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive trial results and analyst upgrade suggest upside potential.
Raised full-year guidance after beating estimates should support sentiment and expectations for continued outperformance.
Upgrade suggests upside.
Street upside framing via a higher price target, partially offset by valuation-overhang and noted insider selling in the writeup.
Approval adds a new royalty stream and validates Halozyme's platform, likely boosting the stock.
AlphAI scores every news story that mentions HALO with an AI model for sentiment and relevance, and aggregates insider trades from HALOZYME THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating and $130 price target for Halozyme (HALO) after Takeda's trial data showed its immunoglobulin treatment reduced infusion times. The stock is near its 52-week high, up 82% in a year. Halozyme also completed a $1.5B convertible notes offering and won a patent case against Merck. The FDA approved a cancer treatment using Halozyme's technology.
2 min readTodd Gordon of Inside Edge Capital suggests rotating out of tech and highlights Halozyme Therapeutics, citing its better-than-expected performance and raised full-year guidance.
2 min readAnalysts updated ratings and price targets for several companies. Notable changes include Crocs upgraded to Overweight with a target of $139, IBM's target raised to $238, Microsoft's target increased to $675, and Morgan Stanley's target cut to $185. Other companies received mixed recommendations and target adjustments.
2 min readTD Cowen maintained its 'Buy' rating for Halozyme Therapeutics (HALO) and raised its price target to $130, up 23.81% from $105. The stock is currently trading at $109.44, which is 7.6% above its GF Value™ of $101.75, indicating overvaluation. Halozyme has a GF Score™ of 89/100, showing strong growth and profitability but moderate financial strength. Insider activity shows significant selling, with $22.1M in shares sold over the last three months.
5 min readH.C. Wainwright reiterated a Buy rating and $130 price target for Halozyme Therapeutics (HALO) after FDA approved Roche's cancer treatment using Halozyme's technology. HALO trades at $111.08, with 17% upside to the target. The approval offers a 12-month adjuvant royalty opportunity for Halozyme, though the addressable population is relatively small. Halozyme also won a patent case against Merck and completed a $1.5B convertible notes offering.
2 min readRoche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.
4 min readTorley Helen (PRESIDENT AND CEO) sold 60,000 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $110.18 ($107.90–$113.69, $6.61M total) across 12 trades over 2026-10-06 to 2026-10-08 under a Rule 10b5-1 trading plan.
2 min readHC Wainwright maintained a Buy rating on Halozyme Therapeutics with a $130 price target, suggesting a 17.3% upside. The firm cited favorable patent rulings against Merck's KEYTRUDA and potential royalties as key factors. A settlement could boost Halozyme's revenue and reduce competition from Novartis.
3 min readA Dutch court ruled Merck's Keytruda Qlex infringes Halozyme's patents, blocking sales in 8 European countries. Halozyme's technology enables rapid delivery of biologics via subcutaneous injections. Enliven Therapeutics aligned with the FDA on a late-stage trial for its leukemia drug relcobatinib, potentially challenging Novartis' and Merck's therapies. Insmed's CFO Sara Bonstein will step down. KymaThera raised $80M for its PI3Kα mutation treatments.
2 min readHalozyme secured a court injunction blocking Merck's Keytruda SC in parts of Europe, reinforcing its IP strategy. The impact on Halozyme's finances depends on further legal outcomes.
1 min read
